Captopril (CAP) was the first angiotensin I-converting enzyme (ACE) inhibitor to be developed and is

widely used in hypertension treatment. Therefore, development of a controlled delivery system for CAP
would bring many advantages for hypertension patients, who compose almost 25% of the world’s
population.4,5 The inclusion complexes were prepared by spray-drying, freeze-drying, kneading, or
lyophilization methods and characterized by nuclear magnetic resonance, Fourier-transformed infrared
spectroscopy, X-ray diffraction, differential scanning calorimetry, and scanning electron microscopy
techniques.

4. Khan MA, Sastry SV, Vaithiyalingam SR, et al. Captopril gastrointestinal therapeutic system coated
with cellulose acetate pseudolatex: evaluation of main effects of several formulations variables. Int J
Pharm. 2000;193:147–156.

5. Jiménez-Martínezb I, Quirino-Barreda T, Villafuerte-Robles L. Sustained delivery of captopril from

floating matrix tablets. Int J Pharm. 2008;362:37–43.